Additional file 1 of Site-specific recombinatorics: in situ cellular barcoding with the Cre Lox system

The C++ code provided in ‘Additional file 1’ computes barcode probabilities (Fig. 3 c) and average number of inversions and excisions (Fig. 3 d) for a Lox barcoding cassette with m Lox sites. With modifications (specified at the end of the file) it also computes the data for Figs. 3 e and 4 e (inset) and distributions shown in Fig. 4 d-f. CPP 12.1 k

Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain Inhibitors

A number of diazepines are known to inhibit bromo- and extra-terminal domain (BET) proteins. Their BET inhibitory activity derives from the fusion of an acetyl-lysine mimetic heterocycle onto the diazepine framework. Herein we describe a straightforward, modular synthesis of novel 1,2,3-triazolobenzodiazepines and show that the 1,2,3-triazole acts as an effective acetyl-lysine mimetic heterocycle. Structure-based optimization of this series of compounds led to the development of potent BET bromodomain inhibitors with excellent activity against leukemic cells, concomitant with a reduction in c-<i>MYC</i> expression. These novel benzodiazepines therefore represent a promising class of therapeutic BET inhibitors

Effects of Renal Denervation Documented in the Austrian National Multicentre Renal Denervation Registry

<div><p>Renal denervation (RDN) is a new procedure for treatment-resistant hypertensive patients. In order to monitor all procedures undergone in Austria, the Austrian Society of Hypertension established the investigator-initiated Austrian Transcatheter Renal Denervation (TREND) Registry. From April 2011 to September 2014, 407 procedures in 14 Austrian centres were recorded. At baseline, office and mean 24-h ambulatory blood pressure (ABP) were 171/94 and 151/89 mmHg, respectively, and patients were taking a median of 4 antihypertensive medications. Mean 24-h ABP changes after 2–6 weeks, 3, 6 and 12 months were -11/-6, -8/-4, -8/-5 and -10/-6 mmHg (p<0.05 at all measurements), respectively. The periprocedural complication rate was 2.5%. Incidence of long-term complications during follow-up (median 1 year) was 0.5%. Office BP and ABP responses showed only a weak correlation (Pearson coefficient 0.303). Based on the data from the TREND registry, ambulatory blood pressure monitoring in addition to office BP should be used for patient selection as well as for monitoring response to RDN. Furthermore, criteria for optimal patient selection are suggested.</p></div

Mean 24-h BP changes after RDN over 12 months of follow-up.

<p>Error bars represent standard error of means. ^‡ p<0.001.</p

Responses to RDN at 2–6 weeks, 3, 6, and 12 months after procedure.

<p>Responses to RDN at 2–6 weeks, 3, 6, and 12 months after procedure.</p

Mean office BP changes after RDN over 12 months of follow-up.

<p>Error bars represent standard error of means. ^‡ p<0.001.</p